ArticleOncoimmunology2016
Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Transcription factors remodel tumor immune microenvironment by impacting multiple immune cells.Discover oncology · 2026Review
- Promising Targets and Drugs for Improving Head and Neck Cancer Response to Radiotherapy.Current pharmaceutical design · 2026Review
- Dysregulated miRNA Expression and Its Association with Immune Checkpoints in Head and Neck Cancer.Cancers · 2025Article
- MiR- 150 deletion promotes lung tumor growth by upregulating P-STAT3 and ROS in MDSCs.Scientific reports · 2025Article
- Erythroid progenitor cell-mediated spleen-tumor interaction deteriorates cancer immunity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Frontiers in immunology · 2025Review
- The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy.Cancer metastasis reviews · 2024Review
- STAT3: Key targets of growth-promoting receptor positive breast cancer.Cancer cell international · 2024Review
- Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives.Journal of nanobiotechnology · 2024Review
- Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors.Cell reports. Medicine · 2024Article
- Review
- STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- STAT3 pathway in cancers: Past, present, and future.MedComm · 2022Review
- Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Review
- Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities.Frontiers in oncology · 2022Review
- Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.Frontiers in medicine · 2022Review
- Review
- The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites.Current oncology reports · 2020Review
- Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2020Article
- Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.Biomolecules & therapeutics · 2020Review
Corrections and comments
- Erratum issuedCorrection.2025
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Cumulative evidence suggests that constitutively activated signal transducer and activator of transcription (STAT3) may contribute to sustaining immunosuppressive status, and that inhibiting STAT3 signaling represents a potential strategy to improve antitumor immunity. In the present study, we observed that high levels phosphorylated of STAT3 are significantly associated with the markers for both myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in human head and neck squamous cell carcinoma (HNSCC). Additionally, we showed that targeting STAT3 signaling with a tolerable selective inhibitor S3I-201 significantly decreased immature myeloid cells such as MDSCs, TAMs and iDCs in genetically defined mice HNSCC model. These findings highlight that targeting STAT3 signaling may be effective to enhance antitumor immunity via myeloid suppressor cells in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.